<DOC>
	<DOCNO>NCT02360891</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis ( ALS ) complex polymorph devastate neurodegenerative disease . Although pathophysiological mechanism underlie development ALS remain fully elucidate , significant advance understand ALS pathogenesis , evidence emerge complex interaction genetic factor dysfunction vital molecular pathway . However , numerous randomize clinical trial ( RCT ) ALS fail generate improve drug treatment . Biomarkers able bring prognostic value distinguish different endophenotypes polymorphic disease could help good select cluster patient order improve RCT outcome . However , little progress make development viable diagnostic , prognostic monitoring marker . This could explain common shortcoming , relatively small sample size , statistically underpowered study design , lack disease control poorly characterize patient cohort . It yet crucial investigator develop validate ALS biomarkers incorporate biomarkers drug development pipeline ALS . The aim present study therefore determine clinical , biological , image , electrophysiological biomarkers prognosis survival without event ( i.e . severe comorbidity , 24 hour non invasive ventilation , tracheotomy ) . This prospective observational multicentric French study cohort 1000 ALS patient . This large multimodal database open international fruitful scientific collaboration .</brief_summary>
	<brief_title>Study Predictive Factors Progression Lateral Amyotrophic Sclerosis</brief_title>
	<detailed_description>This prospective observational multicentric French study cohort 1000 ALS patient , 100 neurological control 200 healthy control follow first sign end disease . The aim present study therefore determine clinical , biological , image , electrophysiological biomarkers prognosis survival without event ( i.e . severe comorbidity , 24 hour non invasive ventilation , tracheotomy ) . Secondary objective notably include ) biomarkers disease progression ii ) biomarkers diagnosis compare control iii ) determination different endophenotypes accord prognosis , genetic profile initial clinical presentation . Criteria assessment notably include detailed medical history , habitus , past present treatment , vascular risk factor , ALSFRS-R , muscular testing , respiratory parameter include early nocturnal saturation apneal profile , detail predetermine clinical presentation , extensive cognitive behavioral examination , extensive blood , cerebrospinal fluid , urines biological test , genetic analysis , multiple brain spinal MRI sequence , electrophysiological test ( i.e . electromyogram , MUNIX , triple stimulation ) . Invasive test optional ( i.e . lumbar puncture , skin biopsy , muscular biopsy ) . The large number patient allow depth statistical analysis , notably establish decisional tree ( CHAID ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Inclusion Criteria ALS patient : Patients suspicion Amyotrophic lateral sclerosis Since first sign ( cramps fasciculation ) first deficit diagnosis work Patient old 18 year Patient able provide inform consent Inclusion Criteria healthy control : Subjects older 18 year ( match population age sex ALS ) Neurological test examination show neurological disorder . Not severe disease life functional prognosis Inclusion Criteria neurological control : Patients typical neurodegenerative disease ALS ( Parkinson 's disease , Alzheimer 's disease ) Not severe disease life functional prognosis Patient old 18 year ( match population age sex ALS ) Patient able provide inform consent Subjects young 18 year Patient unable provide inform consent Having severe disease life functional prognosis Contraindications MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>multimodal biomarkers</keyword>
	<keyword>prognosis</keyword>
	<keyword>endophenotypes</keyword>
</DOC>